Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-line FOLFOX-4 Plus Panitumumab Followed by 5-FU/LV Plus Panitumumab or Single-agent Panitumumab as Maintenance Therapy in Patients With RAS Wild-type, Metastatic Colorectal Cancer: the VALENTINO Study

Next Previous
Search
Trial Profile

First-line FOLFOX-4 Plus Panitumumab Followed by 5-FU/LV Plus Panitumumab or Single-agent Panitumumab as Maintenance Therapy in Patients With RAS Wild-type, Metastatic Colorectal Cancer: the VALENTINO Study

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Panitumumab (Primary) ; Fluorouracil; Fluorouracil/folinic-acid; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
  • Focus Therapeutic Use
  • Acronyms VALENTINO

    • Most Recent Events

    • 19 Jun 2023 Results of pooled analysis data pooled analysis of Valentino, Panama, MACRO-2, COIN-B trials published in the European Journal of Cancer
    • 22 Nov 2021 Results (n=135) published in the British Journal of Cancer
    • 03 Jul 2021 Status changed from active, no longer recruiting to completed, according to Results presented at the 23rd World Congress on Gastrointestinal Cancer.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top